Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.

Shintaro NaritaTakahiro KimuraShingo HatakeyamaKenichi HataTakafumi YanagisawaShinya MaitaShuji ChibaHiromi SatoSoki KashimaAtsushi KoizumiRyohei YamamotoKoichiro TakayamaKatsumi OkaneToshiya IshidaYohei HorikawaTeruaki KumazawaJiro ShimodaTakehiro SuzukiChikara OhyamaShin EgawaKyoko NomuraTomonori Habuchi

Published in: World journal of urology (2022)

The comparison of real-world retrospective cohorts showed that treatment intensification with upfront DOC or upfront ABI promoted better OS compared to ADT alone or CAB in patients with high-volume mCSPC after PSM. However, no difference in OS was observed between upfront DOC and upfront ABI.

Keyphrases

prostate cancer
squamous cell carcinoma
radical prostatectomy
cross sectional
stem cells
radiation therapy
mesenchymal stem cells
locally advanced
combination therapy
replacement therapy